» Articles » PMID: 31949755

Phosphorylated AMP-activated Protein Kinase Expression is Significantly Associated with Poor Clinical Outcomes in Bladder Carcinoma Patients

Overview
Specialty Pathology
Date 2020 Jan 18
PMID 31949755
Authors
Affiliations
Soon will be listed here.
Abstract

The phenotype of p-AMPK has been suggested as a possible marker for diagnosis and/or prognosis in tumors located in different organs. Nonetheless, there are conflicts among the outcomes found in several tumors, and little is proven concerning the correlation between the phenotype of p-AMPK and its clinical significance in urinary bladder carcinomas. Therefore, this research will define the p-AMPK expression patterns, and study the relationship between this pattern of expression, in a panel of urinary bladder carcinomas compared to normal tissues, and clinicopathological features to determine the clinical relevance and the function of p-AMPK in the evolution of bladder cancer. Furthermore, this study will evaluate p-AMPK expression as a diagnostic marker and prognosticator of long term overall survival in bladder cancer patients. This study will utilize the p-AMPK monoclonal antibody using the immunohistochemistry staining standard protocol to identify the location and expression pattern of p-AMPK, which will be graded with respect to the estimated percentage of tumor cells with positive and relative intense stain. 128 cases of urinary bladder carcinoma and 24 non-cancerous bladder tissue samples were employed for the determination of p-AMPK phenotypes applying immunohistochemical staining on tissue microarrays slides. A high score of nuclear p-AMPK immunoexpression has been found in 104 (81.3%) bladder cancer cases, while 24 (100%) control cases showed p-AMPK immunoreactivity. Strong p-AMPK immunohistochemical staining in both epithelial cells and stromal cells has been significantly linked with vascular invasion (-value = 0.002 and -value = 0.011 respectively). Lymph node metastasis showed significant association with p-AMPK expression in tumor epithelial cells (-value = 0.030). The odds of low expression in epithelial cells for a positive lymph node are 3.21 times as great as the odds of low expression in epithelial cells for a negative lymph node. Our findings recommend p-AMPK as a useful biomarker in determining the prognosis of bladder cancer. These preliminary findings suggest that p-AMPK may be a valuable tissue biomarker for predicting a poor prognosis in bladder cancer.

Citing Articles

Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.

Peixoto A, Ferreira D, Miranda A, Relvas-Santos M, Freitas R, Veth T iScience. 2025; 28(2):111758.

PMID: 39906564 PMC: 11791300. DOI: 10.1016/j.isci.2025.111758.

References
1.
Kim J, Yang G, Kim Y, Kim J, Ha J . AMPK activators: mechanisms of action and physiological activities. Exp Mol Med. 2016; 48:e224. PMC: 4855276. DOI: 10.1038/emm.2016.16. View

2.
William W, Kim J, Liu D, Solis L, Behrens C, Lee J . The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2011; 23(1):78-85. PMC: 3276321. DOI: 10.1093/annonc/mdr036. View

3.
Kopsiaftis S, Hegde P, Taylor 3rd J, Claffey K . AMPKα Is Suppressed in Bladder Cancer through Macrophage-Mediated Mechanisms. Transl Oncol. 2016; 9(6):606-616. PMC: 5143351. DOI: 10.1016/j.tranon.2016.07.007. View

4.
Dasgupta B, Chhipa R . Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer. Trends Pharmacol Sci. 2015; 37(3):192-206. PMC: 4764394. DOI: 10.1016/j.tips.2015.11.007. View

5.
Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View